MNPR carries a fresh positive analyst-news signal and strong momentum, but quality sits well below the engine's floor with cash burn, margin compression, high leverage, and an already-reached price target.
Thesis pillars
- Value Trap Margin Compression And Leverage→Stable
- Quality Below Floor Cash Burning→Stable
- Analyst Target Reached Negative Asymmetry→Stable
- +2 more pillars — see the Why tab for full reasoning
Monopar Therapeutics Inc. (MNPR) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $89.76: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum.
Monopar Therapeutics is a clinical-stage biopharmaceutical company advancing ALXN1840 for Wilson disease, licensed from Alexion after it completed a Phase 3 trial meeting its primary endpoint, alongside the MNPR-101 radiopharmaceutical antibody platform paired with zirconium-89,... Read more
Sell if holding. Engine safety override at $89.76: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-09-23Recent Developments — Monopar Therapeutics Inc.
Latest news
- NEWS This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday — benzinga Aug 13, 2026 neutral
- NEWS Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128 — benzinga Aug 13, 2026 neutral
- NEWS Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119 — benzinga Aug 13, 2026 negative
- NEWS BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133 — benzinga Aug 12, 2026 positive
- NEWS Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate — benzinga Aug 12, 2026 negative
Generated 2026-09-23T17:12:16Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $89.76: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $86.97. Score 5.2/10, moderate confidence.
Take-profit target: $111.03 (+23.7% upside). Prior stop was $86.97. Stop-loss: $86.97.
Quality below floor (1.6 < 4.0).
Monopar Therapeutics Inc. trades at a P/E of N/A (forward -50.4). TrendMatrix value score: 7.5/10. Verdict: Sell.
19 analysts cover MNPR with a consensus score of 4.1/5. Average price target: $128.
What does Monopar Therapeutics Inc. do?Monopar Therapeutics is a clinical-stage biopharmaceutical company advancing ALXN1840 for Wilson disease, licensed from...
Monopar Therapeutics is a clinical-stage biopharmaceutical company advancing ALXN1840 for Wilson disease, licensed from Alexion after it completed a Phase 3 trial meeting its primary endpoint, alongside the MNPR-101 radiopharmaceutical antibody platform paired with zirconium-89, lutetium-177 and actinium-225 isotopes under a NorthStar collaboration. The company has no approved products, $140.4 million in cash at year-end 2025, and expects that funding to last through December 2027.